Skip to main content
Full access
Clinical Synthesis
Published Online: 1 January 2013

The Role of Antipsychotic Drugs in the Treatment of Neuropsychiatric Symptoms of Dementia

Abstract

Patients with dementia frequently experience comorbid behavioral and psychiatric symptoms that are harmful to both patients and their caregivers and contribute to the high healthcare costs associated with Alzheimer’s dementia. Despite their frequent use in the past, there is limited evidence to support the efficacy of first-generation antipsychotics. Second-generation antipsychotics may be modestly helpful for reducing global neuropsychiatric symptoms, psychosis, and agitation/aggression but are associated with potentially serious adverse reactions. The decision to utilize an antipsychotic requires thoughtful consideration of the potential risks and benefits for the individual patient.

Abstract

Patients with dementia frequently experience comorbid behavioral and psychiatric symptoms, also known as neuropsychiatric symptoms of dementia. Neuropsychiatric symptoms are harmful to both patients and their caregivers, and contribute to the high healthcare costs associated with Alzheimer’s dementia. Since the discovery of neuroleptic medications in the 1950s, antipsychotic medications have been the preferred drug option for the treatment of behavioral and psychiatric symptoms of dementia. Despite their frequent use in the past, there is limited evidence to support the efficacy of first-generation antipsychotics in this population. Second-generation antipsychotics may be modestly helpful for reducing global neuropsychiatric symptoms, psychosis, and agitation/aggression in demented older adults. However, second-generation antipsychotics are associated with potentially serious adverse reactions in elderly adults, which may undermine the potential benefits. In clinical practice, second-generation antipsychotics are prescribed for demented patients with distressing or dangerous behavioral disturbances that fail to respond adequately to nonpharmacological approaches. The decision to utilize an antipsychotic requires thoughtful consideration of the potential risks and benefits for the individual patient.

Formats available

You can view the full content in the following formats:

Information & Authors

Information

Published In

History

Published online: 1 January 2013
Published in print: Winter 2013

Authors

Details

Notes

Address correspondence to Corinna Keenmon, M.D., Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, 300 UCLA Medical Plaza, Suite 2420, Los Angeles, CA 90095-1733; e-mail: [email protected].

Funding Information

Author Information and CME Disclosure
Corinna Keenmon, M.D., Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA
Dr. Keenmon reports no competing interests.
David Sultzer, M.D., Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, and Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA
Dr. Sultzer reports the following: Consultant: Otsuka Pharmaceuticals; Research Support and Consultant: Eli Lilly.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Focus

PPV Articles - Focus

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share